Evidence map›Paper›PMID 34604105›Full record

ArticleFrontiers in cellular and infection microbiology2021

Gilbert's Syndrome and the Gut Microbiota - Insights From the Case-Control BILIHEALTH Study.

Patrick A Zöhrer, Claudia A Hana, Nazlisadat Seyed Khoei, Christine Mölzer, Marlies Hörmann-Wallner, Anela Tosevska, Daniel Doberer, Rodrig Marculescu, Andrew C Bulmer, Craig W Herbold and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Potential and Challenges ofFoods (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Patrick A ZöhrerDepartment of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
Claudia A HanaDepartment of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
Nazlisadat Seyed KhoeiDepartment of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
Christine MölzerSchool of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.
Marlies Hörmann-WallnerInstitute for Dietetics and Nutrition, University of Applied Sciences FH JOANNEUM, Graz, Austria.
Anela TosevskaDepartment of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
Daniel DobererClinical Institute of Laboratory Medicine, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Rodrig MarculescuDepartment of Clinical Pharmacology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Andrew C BulmerSchool of Pharmacy and Medical Sciences and Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.
Craig W HerboldDivision of Microbial Ecology, Department of Microbiology and Ecosystem Science, Centre for Microbiology and Environmental Systems Science, University of Vienna, Vienna, Austria.
David BerryDivision of Microbial Ecology, Department of Microbiology and Ecosystem Science, Centre for Microbiology and Environmental Systems Science, University of Vienna, Vienna, Austria.
Karl-Heinz WagnerDepartment of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
University of Vienna · ATMedical University of Vienna · ATFH JOANNEUM University of Applied Sciences · ATGriffith University · AUUniversity of Aberdeen · GBVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heme catabolite bilirubin has anti-inflammatory, anti-oxidative and anti-mutagenic effects and its relation to colorectal cancer (CRC) risk is currently under evaluation. Although the main metabolic steps of bilirubin metabolism, including the formation of stercobilin and urobilin, take place in the human gastrointestinal tract, potential interactions with the human gut microbiota are unexplored. This study investigated, whether gut microbiota composition is altered in Gilbert's Syndrome (GS), a mild form of chronically elevated serum unconjugated bilirubin (UCB) compared to matched controls. Potential differences in the incidence of CRC-associated bacterial species in GS were also assessed. To this end, a secondary investigation of the BILIHEALTH study was performed, assessing 45 adults with elevated UCB levels (GS) against 45 age- and sex-matched controls (C). Fecal microbiota analysis was performed using 16S rRNA gene sequencing. No association between mildly increased UCB and the composition of the gut microbiota in this healthy cohort was found. The alpha and beta diversity did not differ between C and GS and both groups showed a typical representation of the known dominant phyla. Furthermore, no difference in abundance of

Indexed as

Gastrointestinal MicrobiomeGilbert DiseaseCase-Control StudiesEubacterialesFemaleHumansRNA, Ribosomal, 16SRNA, Ribosomal, 16S16S rRNA genebilirubincolorectal cancermicrobiomemicrobiotaUGT1A1unconjugated bilirubin

Identifiers

PMID34604105
PMCPMC8481893
OpenAlexW3198966092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.